The psychosocial impact of the COVID-19 pandemic on MGUS, smouldering and active myeloma patients: findings from an international survey

Stephen Quinn, Lesley Anderson, Lynne Lohfeld, Charlene M. McShane

Research output: Contribution to journalLetterpeer-review

Abstract

Early in the COVID‐19 pandemic, the UK National Health Service (NHS) identified multiple myeloma (MM) patients as a “clinically extremely vulnerable” population1. In contrast, the clinical significance of COVID‐19 to MM precursors, monoclonal gammopathy of undermined significance (MGUS)2 and smouldering multiple myeloma (SMM)3, remains unknown.

Here for the first time we summarise the impact of the COVID‐19 pandemic on 274 MM spectrum individuals (66 MGUS, 33 SMM, 175 MM) who participated in the IMPaCCT (Investigating the impact of COVID‐19 on caregivers and patients) study. The first wave of this online international longitudinal study took place between 24 April‐14 July 2020.
Original languageEnglish
JournalBritish Journal of Haematology
Volume194
Issue number2
Early online date25 Mar 2021
DOIs
Publication statusPublished - 15 Jul 2021

Keywords

  • COVID-19
  • psychosocial needs
  • myeloma
  • monoclonal gammopathy of undetermined significance (MGUS)
  • smouldering myeloma

Fingerprint

Dive into the research topics of 'The psychosocial impact of the COVID-19 pandemic on MGUS, smouldering and active myeloma patients: findings from an international survey'. Together they form a unique fingerprint.

Cite this